Journal of Physiology and Biochemistry

, Volume 68, Issue 4, pp 563–572 | Cite as

Effect of zinc supplementation on type 2 diabetes parameters and liver metallothionein expressions in Wistar rats

Original Paper

Abstract

Zinc is a trace metal and acts as an active component of various enzymes. Zinc deficiency has been suggested to be associated with the development of diabetes. The present study investigated the role of zinc supplementation on prevention of diabetic conditions. A double-disease model mimicking hyperlipidemia and type 2 diabetes was created by applying high-fat diet and streptozotocin (STZ) to Wistar rats. We demonstrated that zinc supplementation improved symptoms of diabetes such as polydipsia and increased serum level of high-density lipoprotein cholesterol, indicating that zinc supplementation has a potential beneficial effect on diabetic conditions. The level of maldondialdehyde (MDA), an oxidative stress marker, was reduced in liver by zinc supplementation in high fat-fed rats with or without STZ injection. Meanwhile, we observed an increase in the expression of metallothioneins (MTs) in liver of rats treated with zinc. This suggests that the induction of MTs in liver, which has been shown to be important in scavenging free radicals, could be one of the underlying mechanisms of zinc supplementation on reducing MDA levels in liver. Finally, we found that zinc levels in liver were increased while there was no change in serum zinc levels, indicating that local zinc level might be a critical factor for the induction of MTs. Also, the level of MTs could potentially be an index of zinc bioavailability. Taken together, these results suggest that both zinc and MT could play an important role in balancing nutrition and metabolism to prevent diabetic development.

Keywords

Zinc Diabetes Hyperglycemia Dyslipidemia Oxidative stress 

References

  1. 1.
    Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A (2001) Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus Journal of the American. J Am Coll Nutr 20:212–218PubMedGoogle Scholar
  2. 2.
    Baraboy VA, Petrina LG (2003) Metallothioneins: the structure and action mechanisms. Ukr Biokhim Zh 75:28–36Google Scholar
  3. 3.
    Barbato JC, Catanescu O, Murray K, DiBello PM, Jacobsen DW (2007) Targeting of metallothionein by l-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol 27:49–54PubMedCrossRefGoogle Scholar
  4. 4.
    Barter PJ, Rye KA (1996) High density lipoproteins and coronary heart disease. Atherosclerosis 121:1–12PubMedCrossRefGoogle Scholar
  5. 5.
    Begin-Heick N, Dalpe-Scott M, Rowe J, Heick HM (1985) Zinc supplementation attenuates insulin secretory activity in pancreatic islets of the ob/ob mouse. Diabetes 34:179–184PubMedCrossRefGoogle Scholar
  6. 6.
    Beletate V, El Dib RP, Atallah AN (2007) Zn supplementation for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev 24: CD005525Google Scholar
  7. 7.
    Cao J, Henry PR, Davis SR, Cousins RJ, Miles RD, Littell RC, Ammerman CB (2002) Relative bioavailability of organic zinc sources based on tissue zinc and metallothionein in chicks fed conventional dietary zinc concentrations. Anim Feed Sci Tech 101:161–170CrossRefGoogle Scholar
  8. 8.
    Chen MD, Liou SJ, Lin PY, Yang VC, Alexander PS, Lin WH (1998) Effects of zinc supplementation on the plasma glucose level and insulin activity in genetically obese (ob/ob) mice. Biol Trace Elem Res 61:303–311PubMedCrossRefGoogle Scholar
  9. 9.
    Chien K, Cai T, Hsu H, Su T, Chang W, Chen M, Lee Y, Hu FB (2009) A prediction model for type 2 diabetes risk among Chinese people. Diabetologia 52:443–450PubMedCrossRefGoogle Scholar
  10. 10.
    Coccheri S (2007) Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67:997–1026PubMedCrossRefGoogle Scholar
  11. 11.
    Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, Galan P, Hercberg S (2006) Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 84:395–399PubMedGoogle Scholar
  12. 12.
    Deedwania P (2011) Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens 13:52–59CrossRefGoogle Scholar
  13. 13.
    Erdal N, Gurgul S, Kavak S, Yildiz A, Emre M (2011) Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. Biol Trace Elem Res 140:342–353PubMedCrossRefGoogle Scholar
  14. 14.
    Grungreiff K, Reinhold D (2005) Liver cirrhosis and "liver" diabetes mellitus are linked by zinc deficiency. Med Hypotheses 64:316–317PubMedCrossRefGoogle Scholar
  15. 15.
    Hussein AM, Omar NM, Sakr H, Elsamanoudy AZ, Shaheen D (2011) Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus. Can J Physiol Pharmacol 89:216–226CrossRefGoogle Scholar
  16. 16.
    Irato P, Santovito G, Piccinni E, Albergoni V (2001) Oxidative burst and metallothionein as a scavenger in macrophages. Immunol Cell Biol 79:251–254PubMedCrossRefGoogle Scholar
  17. 17.
    Ismael PH, Yesica AF, Ricardo MZ (2010) Analysis of the membrane fluidity of erythrocyte ghosts in diabetic, spontaneously hypertensive rats. Acta Diabetologica 47:47–55CrossRefGoogle Scholar
  18. 18.
    Kehkashan P, Rashid Khan M, Mujeeb M, Siddiqui WA (2010) Protective effects of Pycnogenol (R) on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact 186:219–227CrossRefGoogle Scholar
  19. 19.
    Lastra G, Manrique C (2007) The expanding role of oxidative stress, renin angiotensin system, and beta-cell dysfunction in the cardiometabolic syndrome and type 2 diabetes mellitus. Antioxid Redox Signal 9:943–954PubMedCrossRefGoogle Scholar
  20. 20.
    Marreiro DN, do Perpetuo Socorro C, Martins M, de Sousa SS, Ibiapina V, Torres S, Pires LV, do Nascimento Nogueira N, Lima JM, do Monte SJ (2007) Urinary excretion of zinc and metabolic control of patients with diabetes type 2. Biol Trace Elem Res 120:42–50PubMedCrossRefGoogle Scholar
  21. 21.
    Matsunami T, Sato Y, Sato T, Ariga S, Shimomura T, Yukawa M (2010) Oxidative stress and gene expression of antioxidant enzymes in the streptozotocin-induced diabetic rats under hyperbaric oxygen exposure. Int J Clin Exp Pathol 3:177–188Google Scholar
  22. 22.
    Meika F, Peter P, Samir S (2010) Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: a meta-analysis of randomised controlled trials. Atherosclerosis 210:344–352CrossRefGoogle Scholar
  23. 23.
    Meika F, Samir S (2010) Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal 13:1549–1573CrossRefGoogle Scholar
  24. 24.
    Mitsutake R, Miura SI, Zhang B, Saku K (2010) HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol 143:72–78PubMedCrossRefGoogle Scholar
  25. 25.
    Pan HZ, Zhang L, Guo MY (2010) The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 47:71–76PubMedCrossRefGoogle Scholar
  26. 26.
    Roussel AM, Kerkeni A, Zouari N, Mahjoub S, Matheau JM, Anderson RA (2003) Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 22:316–321PubMedGoogle Scholar
  27. 27.
    Souto SB, Souto EB, Braga DC, Medina JL (2011) Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 67:653–661PubMedCrossRefGoogle Scholar
  28. 28.
    Sprietsma JE, Schuitemaker GE (1994) Diabetes can be prevented by reducing insulin production. Med Hypotheses 42:15–23PubMedCrossRefGoogle Scholar
  29. 29.
    Suzuki H, Asakawa A, Li JB, Tsai M, Amitani H, Ohinata K, Komai M, Inui A (2011) Zinc as an appetite stimulator—the possible role of zinc in the progression of diseases such as cachexia and sarcopenia. Recent Pat Food Nutr Agric 3:226–231PubMedCrossRefGoogle Scholar
  30. 30.
    Viarengo A, Burlando B, Ceratto N, Panfoli I (2000) Antioxidant role of metallothioneins: a comparative overview. Cell Mol Biol 46:407–417PubMedGoogle Scholar
  31. 31.
    Wong KC, Wang ZQ (2006) Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 73:126–134PubMedCrossRefGoogle Scholar
  32. 32.
    Wu YT, Sun Z, Che SP, Chang H (2004) Effects of zinc and selenium on the disorders of blood glucose and lipid metabolism and its molecular mechanism in diabetic rats. Wei Sheng Yan Jiu 33:70–73PubMedGoogle Scholar
  33. 33.
    Yu M, Zhou W, Song Y, Yu F, Li D, Na S, Zou G, Zhai M, Xie C (2011) Development of mesenchymal stem cell-implant complexes by cultured cells sheet enhances osseointegration in type 2 diabetic rat model. Bone 49:387–394PubMedCrossRefGoogle Scholar

Copyright information

© University of Navarra 2012

Authors and Affiliations

  1. 1.School of Republic HealthJilin UniversityChangchunPeople’s Republic of China
  2. 2.Graduate School of Jilin UniversityChangchunPeople’s Republic of China
  3. 3.Jilin Provincial People’s ProcuratorateChangchunPeople’s Republic of China

Personalised recommendations